Prescription drug denials by private insurers rise 25% (2016-2023). Sarepta gene therapy linked to patient deaths. ICE gains Medicaid data access. ACA insurers seek 2026 rate hikes. Implications for U.S. insurance, regulatory compliance, and patient access.

HHS and CMS unveil Most Favored Nation drug pricing model targeting pharmaceutical manufacturers to align U.S. drug prices with international benchmarks and reduce costs.